Pentylenetetrazole-induced kindling as a model metabolic syndrome

Bidnyuk, V. K.; Pervak, M. P.; Poshyvak, O. B.; Yehorenko, O. S.; Varava, S. V.; Godlevsky, L. S.; Haustov, O. O.

dc.contributor.author	Bidnyuk, V. K.	en
dc.contributor.author	Pervak, M. P.	en
dc.contributor.author	Poshyvak, O. B.	en
dc.contributor.author	Yehorenko, O. S.	en
dc.contributor.author	Varava, S. V.	en
dc.contributor.author	Godlevsky, L. S.	en
dc.contributor.author	Haustov, O. O.	en
dc.date.accessioned	2022-12-09T08:45:29Z
dc.date.available	2022-12-09T08:45:29Z
dc.date.issued	2022
dc.identifier.citation	Pentylenetetrazole-induced kindling as a model metabolic syndrome / V. K., Bidnyuk, M. P. Pervak, O. B. Poshyvak et al // Acta neurobiologia experimentalis: II 12th Neuronus 2022 Neuroscience Forum, 15–17 october 2022, Krakov, Poland. Vol. 82. P. 95.	en
dc.identifier.uri	https://repo.odmu.edu.ua:443/xmlui/handle/123456789/11715
dc.description.abstract	Data on the relationship between epilepsy and metabolic syndrome justified the evaluation of MS markers expression in PTZ-kindled rats. PTZ kindling was induced in four months aged male Wistar rats with three weeks epileptogen (35.0 mg/kg, i.p.) administration. Those animals with fully developed generalized seizures were used for investigations. The glucose tolerance test (GTT) was followed by a significant rising in blood glucose level 30 min after glucose i.p. administration (2.0 g/kg) up to 395.7+47.2 mg/dl), which exceeded the control data by 1.74 times (P<0.001). Insulin tolerance test (0.75 U of insulin/kg) revealed in 15 min after glucose i.p. administration (2.0 g/kg) up to 114.3+15.7 mg/dl), which exceed the control data by 31.3% (P<0.001).	en
dc.language.iso	en	en
dc.subject	Pentylenetetrazole-induced kindling	en
dc.subject	model metabolic syndrome	en
dc.subject	epilepsy	en
dc.subject	Insulin tolerance test	en
dc.title	Pentylenetetrazole-induced kindling as a model metabolic syndrome	en
dc.type	Article	en